FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live JUBILANT message board: Is JUBILANT buy or sell? Should I buy JUBILANT shares? Why are JUBILANT shares falling? Should I invest in JUBILANT stock?

forum

JUBILANT Share Price Discussion

Jubilant Life Sciences Ltd.
NSE: JUBILANT | BSE: 530019 | ISIN: INE700A01033 | Sector: Pharmaceuticals and health care
N
Reputation: 4,625 • Jun 2 5:08 AM
Hold Jubilant Life Sciences; target of Rs 414: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Jubilant Life Sciences with a target price of Rs 414 in its research report dated Jun 01, 2020.
Moneycontrol
Like
Reply
NSE:JUBILANT price when posted: 487.45
Recent posts in JUBILANT
N
Reputation: 4,625 • Jul 31 1:53 AM
Remdesivir shortage to ease in August as existing suppliers boost capacity, new manufacturers enter
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Moneycontrol
Like
Reply
M
Reputation: 79,353 • Jul 31 5:56 AM

Type
Buy
Instrument
JUBILANT
Entry Price
₹815
Price@Trade
₹803.15
Target Price
₹900
Stop Price
₹795
Valid Till
Jul 31, 2020 3:20 AM
Margin
₹81,500 approx for 100 Qty
Status
Exited before entry
Like
Reply (1)
C
Reputation: -9 • Jul 30 7:19 AM

Type
Buy
Instrument
JUBILANT
Entry Price
₹787
Price@Trade
₹787
Target Price
₹793
Stop Price
₹784.5
Valid Till
Jul 30, 2020 3:20 AM
Margin
₹78,700 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹784.5
Net P&L
-₹250 (-0.32%)
Like
Reply (1)
N
Reputation: 4,625 • Jul 30 2:28 AM
Trade Spotlight: Dr Reddy’s, IndusInd Bank, Nestle, Maruti and Jubilant Life in focus
Indian market witnessed profit-taking at higher levels on Wednesday and the trend is likely to remain volatile on Thursday as well ahead of June F&O expiry.
Moneycontrol
Like
Reply

JUBILANT - chart - 1088729
Buy JUBILANT@770 Tg. 810/1490 CB SL 650
Like
Reply
N
Reputation: 4,625 • Jul 29 3:08 AM
Dr Reddy's expects to launch Remdesivir in August
On another antivral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data hasn't been statistically significant.
Moneycontrol
Like
Reply